Milestone Pharmaceuticals submits NDA to FDA for etripamil

Milestone Pharmaceuticals announced the submission of a New Drug Application to the U.S. FDA for etripamil for the treatment of paroxysmal supraventricular tachycardia. PVST is a condition characterized by an abnormality in the electrical system of the heart causing patients to have unexpected, often severely symptomatic episodes of rapid heart rate. Representing the largest data package ever studied in PSVT, the company believes the clinical trial program demonstrates that etripamil provided superior time to conversion to normal heart rhythm compared to placebo. The primary analysis and supportive assessments from the pivotal RAPID Phase 3 clinical trial were recently published in The Lancet.